EA201691265A1 - Соединения агонисты gpr142 - Google Patents

Соединения агонисты gpr142

Info

Publication number
EA201691265A1
EA201691265A1 EA201691265A EA201691265A EA201691265A1 EA 201691265 A1 EA201691265 A1 EA 201691265A1 EA 201691265 A EA201691265 A EA 201691265A EA 201691265 A EA201691265 A EA 201691265A EA 201691265 A1 EA201691265 A1 EA 201691265A1
Authority
EA
Eurasian Patent Office
Prior art keywords
gpr142
agonists
connections
group
chronoch
Prior art date
Application number
EA201691265A
Other languages
English (en)
Inventor
Тяньвэй Ма
Ми Эмили Цзэн
Чжи Лун Ху
Лянь Чжу Лю
Цзинье Чжоу
Original Assignee
Эли Лилли Энд Компани
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Эли Лилли Энд Компани filed Critical Эли Лилли Энд Компани
Publication of EA201691265A1 publication Critical patent/EA201691265A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/88—Nitrogen atoms, e.g. allantoin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

Настоящее изобретение относится к соединениям формулыгде R выбран из группы, состоящей из СН, СН(СН), CHCN, CHCHF, CHCF,СНСНОСНи СНС(О)ОСН(СН)Rвыбран из группы, состоящей из CF, OCFи Cl; Rвыбран из группы, состоящей из Н и F; или их фармацевтически приемлемой соли.
EA201691265A 2014-02-14 2015-01-22 Соединения агонисты gpr142 EA201691265A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/CN2014/072083 WO2015120610A1 (en) 2014-02-14 2014-02-14 Gpr142 agonist compound
PCT/CN2015/071286 WO2015120768A1 (en) 2014-02-14 2015-01-22 Gpr142 agonist compounds

Publications (1)

Publication Number Publication Date
EA201691265A1 true EA201691265A1 (ru) 2016-11-30

Family

ID=53799520

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201691265A EA201691265A1 (ru) 2014-02-14 2015-01-22 Соединения агонисты gpr142

Country Status (10)

Country Link
US (1) US9861613B2 (ru)
EP (1) EP3105207B1 (ru)
JP (1) JP6298172B2 (ru)
CN (1) CN106170478B (ru)
AU (1) AU2015218135B2 (ru)
CA (1) CA2935109A1 (ru)
EA (1) EA201691265A1 (ru)
ES (1) ES2693545T3 (ru)
MX (1) MX2016010411A (ru)
WO (2) WO2015120610A1 (ru)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016138631A1 (en) 2015-03-03 2016-09-09 Eli Lilly And Company Imidazo benzamide compounds
WO2018014337A1 (en) * 2016-07-22 2018-01-25 Eli Lilly And Company 3-Chloro-N- [ (1R, 3S) -3- [5- (3, 5-dimethylimidazol-4-yl) -4H-1, 2, 4-triazol-3-yl] cyclohexyl] -N-methyl-benzamide
JP7391055B2 (ja) 2018-07-04 2023-12-04 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｇｐｒ１４２アゴニストとしてのトリアゾールベンズアミド誘導体

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005214349B2 (en) * 2004-02-12 2011-11-03 Transtech Pharma, Inc. Substituted azole derivatives, compositions, and methods of use
EP1877401A2 (en) * 2005-04-15 2008-01-16 Elan Pharmaceuticals Inc. Novel compounds useful for bradykinin b1 receptor antagonism
US7754717B2 (en) 2005-08-15 2010-07-13 Amgen Inc. Bis-aryl amide compounds and methods of use
US20090270394A1 (en) * 2008-04-28 2009-10-29 Galemmo Jr Robert Cyclylamine derivatives as calcium channel blockers
US8188098B2 (en) * 2008-05-19 2012-05-29 Hoffmann-La Roche Inc. GPR119 receptor agonists
US8653125B2 (en) * 2009-03-05 2014-02-18 Shionogi Co., Ltd. Cyclohexane derivative having NPY Y5 receptor antagonism
AR079170A1 (es) * 2009-12-10 2011-12-28 Lilly Co Eli Compuesto de ciclopropil-benzamida-imidazo-benzazepina inhibidor de diacil-glicerol aciltransferasa, sal del mismo, composicion farmaceutica que lo comprende, su uso para preparar un medicamento util para el tratamiento de obesidad o para mejorar la sensibilidad a insulina y compuesto intermedio par

Also Published As

Publication number Publication date
EP3105207B1 (en) 2018-08-22
JP6298172B2 (ja) 2018-03-20
EP3105207A1 (en) 2016-12-21
EP3105207A4 (en) 2017-06-21
WO2015120768A1 (en) 2015-08-20
US9861613B2 (en) 2018-01-09
CA2935109A1 (en) 2015-08-20
ES2693545T3 (es) 2018-12-12
AU2015218135A1 (en) 2016-07-14
WO2015120610A1 (en) 2015-08-20
CN106170478B (zh) 2019-04-09
MX2016010411A (es) 2016-10-17
JP2017505797A (ja) 2017-02-23
AU2015218135B2 (en) 2017-06-08
CN106170478A (zh) 2016-11-30
US20170165234A1 (en) 2017-06-15

Similar Documents

Publication Publication Date Title
EA201891024A1 (ru) Соединения-ингибиторы tank-связывающей киназы
CY1120705T1 (el) Καινοφανεις αναστολεις αποακετυλασων ιστονων
EA201692203A1 (ru) Соединения, ингибирующие tank-связывающую киназу
EA201791420A1 (ru) Соединения триазолопиримидина и их применения
EA201790407A1 (ru) Зонды для визуализации белка хантингтина
EA201790395A1 (ru) Производные аминотриазина, подходящие для применения в качестве соединений-ингибиторов tank-связывающей киназы
EA201691799A1 (ru) Бициклические соединения в качестве ингибиторов продукции аутотаксина (atx) и лизофосфатидиловой кислоты (lpa)
EA201692193A1 (ru) Способы получения ингибитора jak1 и его новых форм
EA201691302A1 (ru) Новые гетероциклические соединения
EA201792021A1 (ru) Ингибитор jak
EA201890522A1 (ru) Способ получения противогрибковых соединений
EA201890899A1 (ru) Модуляторы фарнезоидного x-рецептора
EA201692219A1 (ru) Способы получения противовирусных соединений
TR201906366T4 (tr) Polisiklik-karbamoilpiridon bileşiklerinin sentezi.
EA201791304A1 (ru) Производные изохинолина для лечения вич
EA201791684A1 (ru) Селективные ингибиторы bace1
EA201790112A1 (ru) Гетероциклические соединения и их применение в качестве ингибиторов орфанного рецептора гамма-t, родственного рецепторам ретиноидов (ror)
EA201790983A1 (ru) Синтез копанлисиба и его дигидрохлорида
EA201791896A1 (ru) Дезацетокситубулизин н и его аналоги
TN2018000020A1 (en) Colony stimulating factor-1 receptor (csf-1r) inhibitors.
EA201691071A1 (ru) Фенилтриазолопиридиновые соединения
EA201790400A1 (ru) Зонды для визуализации белка хантингтина
EA201691150A1 (ru) Соединения изопропилтриазолопиридина
EA201690879A1 (ru) Новое триазолопиридиновое соединение
EA201790982A1 (ru) Синтез копанлисиба и его дигидрохлорида